New Products

Oct 16, 2018

DNAnexus Apollo

DNAnexus has released its DNAnexus Apollo platform for clinico-genomic data science exploration, analysis, and discovery. The platform provides a scalable cloud environment, flexible data models, as well as intuitive analysis and visualization tools for research and development teams. According to DNAnexus, pharmaceutical research and development teams can use the platform in their translational informatics research to quickly tests hypotheses and learn more about the mechanisms of action, biomarkers and targets. 

Oct 15, 2018

Roche NGS Avenio Tumor Tissue Analysis Kits

Roche has launched three next-generation sequencing Avenio tumor tissue analysis kits for oncology research: the Avenio Tumor Tissue Targeted Kit, Expanded Kit, and Surveillance Kit. The new kits complement the company's NGS ctDNA kits. They use formalin-fixed paraffin-embedded tissue and have a workflow of five days. The Avenio Tumor Tissue Targeted Kit covers 17 genes to identify guideline-related biomarkers. The Avenio Tumor Tissue Expanded Kit is a 77-gene assay with both guideline-related and emerging biomarkers. The Avenio Tumor Tissue Surveillance Kit covers 197 genes and is intended for establishing a baseline for variants in longitudinal tumor burden monitoring.

Oct 15, 2018

Empirical Biosciene EB Pure Total RNA & DNase 1 Digestion Kits

Emiprical Bioscience has launched its EB Pure Total RNA kit and the EB Pure DNase 1 Digestion kit to quickly and reliably purify RNA from cells or soft tissue. 

The firm's EB Pure Total RNA Kit reversibly binds RNA under optimized conditions, allowing researchers to remove proteins and other contaminants from the sample. The tool also allows RNA binding in high-salt and elution in a low-salt buffer. Each column can bind up to 100 microliters and does not need organic extractions or additional precipitations. The tool produces high and stable recovery rates within 20 minutes. The EB Pure DNase 1 Digestion kit can be used alongside the EB Pure Total RNA Kit in order for further DNA removal, the firm said.  

Oct 11, 2018

Pacific Biosciences Sequel System 6.0

Pacific Biosciences has launched updates to its Sequel sequencing system, including software version 6.0, reagents version 3.0, and SMRT cells 1M v3. Together, these changes, which are part of the Sequel System 6.0 release, result in sequence reads with greater than 99 percent accuracy, throughput of up to 50 gigabases per SMRT cell, and average read lengths of up to 100 kilobases, depending on the insert size, the firm said. For amplicon sequencing and RNA sequencing, customers can generate up to 500,000 reads with single-read accuracy greater than 99 percent. For whole-genome sequencing, customers can generate up to 20 gigabases of data per SMRT cell, with average read lengths of up to 30 kilobases.

Oct 11, 2018

Cellecta CloneTracker XP Expressed Lentiviral Barcode Library and Barcoded CRISPR Library

Cellecta has launched the CloneTracker XP Expressed Lentiviral Barcode Library and CloneTracker XP Barcoded CRISPR Library product lines. The new CloneTracker XP Barcode Libraries differ from Cellecta's standard CloneTracker Barcode Library in that the unique DNA sequence is designed to express on an RNA transcript in the cells. The libraries can therefore be detected by either DNA or RNA sequencing. Researchers can use these libraries to label several million cells each with a unique barcode, subsequently performing NGS to sort out sub-populations of progeny cells derived from the original progenitors at any point during the experiment.

Additionally, a variation of the new CloneTracker XP barcode labeling product introduces a gene effector, in this case CRISPR sgRNA, into the barcode library. Each effector targets and disrupts a specific gene in each of the cells that pick up a barcode. In combination with cell-specific barcode tracking, this knockout helps researchers see how specific genetic disruptions change the cells' characteristics while simultaneously identifying the genetic pathways that are activated to produce them. The firm offers two small, pre-made CloneTracker XP Barcoded CRISPR knockout libraries targeting 27 human and mouse anti-cancer genes, as well as custom library development services for CloneTracker XP Barcoded CRISPR Libraries. The CloneTracker XP Expressed Barcode Libraries are available with barcodes expressed in the 3′- or 5′-UTR of an RNA transcript, and with fluorescent or chemiluminescent reporters.

Oct 11, 2018

Paragon Genomics CleanPlex UMI Lung Cancer Panel

Paragon Genomics will introduce its research-use-only CleanPlex UMI Lung Cancer Panel at the upcoming American Society of Human Genetics Meeting. The panel is a targeted resequencing assay designed for the detection of ultralow-frequency variants across the hotspot regions of 23 genes frequently associated with lung cancer. The CleanPlex UMI technology incorporates unique molecular identifiers that distinguish between the two strands of DNA, enabling correction of PCR and sequencing errors to achieve more accurate results. The product can be used to prepare sequencing-ready libraries in a single-tube format in 3.5 hours, and variants at 0.1 percent allele frequency can be detected with high specificity using only 30 ng of DNA, Paragon said. CleanPlex NGS Panels are available for use with Illumina or Life Technologies Ion Torrent platforms.

Oct 10, 2018

Oxford Nanopore 'Rev D' Flow Cells

Oxford Nanopore Technologies has released a new version of the flow cell for the MinIon and GridIon sequencers that include the 'Rev D' ASIC. The new flow cells can be used for a longer time and yield up to 30 gigabases of data.

Oct 10, 2018

Oxford Nanopore MinIT

Oxford Nanopore Technologies has launched the MinIT, a compute module for use with the MinIon sequencer. MinIT is equipped with a Nvidia AGX system for real-time high-throughput data analysis and is preconfigured with software for MinIon set up and operation. Users can operate the module using either a tablet or mobile phone. MinIT runs both the instrument software MinKnow and the real-time analysis platform for nanopore data EPI2ME. Customers can power the tool using battery packs, which are available separately.

Oct 10, 2018

L7 Enterprise Science Platform 2.0

L7 Informatics, formerly known as Lab7 Systems, has introduced version 2.0 of its Enterprise Science Platform, featuring a validated, pre-built connection to the Microsoft Genomics service so users can run bioinformatics pipelines on the Microsoft Azure cloud. The release also includes workflow chaining to support multivariable processes, as well as support for next-generation sequencing, translational research, and cell therapy applications, plus a new user interface.

Oct 09, 2018

MDNA Life Sciences Mitomic Prostate Test

MDNA Life Sciences has announced the UK release for its PCR-based Mitomic Prostate Test (MPT). The MPT is a liquid biopsy assay optimized for the early detection of prostate cancer in advance of biopsy. The firm designed the MPT for testing men with clinical suspicion of prostate cancer to determine their likelihood of clinically significant cancer that may benefit from rapid intervention. The test will run on MDNA's CE-IVD kit, which contains the needed reagents to process up to 21 patient samples at a time.

Oct 05, 2018

Stratify Genomics Prompt Prostate Cancer Test

Stratify Genomics has announced Prompt, its new lab-developed test to track a man's genetic predisposition to prostate cancer. According to the firm, Prompt incorporates genetic information from several prostate cancer-risk associated SNPs. Using population-based analyses, the test reports how many men (out of 100) with a given genetic score would go on to develop prostate cancer. Clinicians can perform the test with a cheek swab sample to help men know their individual risk and potentially identify high-risk individuals.

Oct 04, 2018

Precipio HemeScreen

Precipio this week commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, JAK2 exon 12, and MPL genes, which are critically important to developing the clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.

Oct 03, 2018

Seq2Know Celiac Disease Testing

Seq2Know has begun offering celiac disease testing. The firm's test includes the sequencing of the DQA1 and DQB1 genes that have been associated with celiac disease. All tests will be ordered directly from Seq2Know.com and will be reviewed by PWNHealth to ensure the appropriateness of the test, the company said. 

Sep 28, 2018

MNG Xpress Exome

MNG Laboratories has launched the MNG Xpress Exome, a diagnostic exome sequencing test to identify mutations in Mendelian disorders. The test, which has a turnaround time of 10 to 14 days, costs $4,895 for a trio and $3,295 for proband-only testing.

Sep 28, 2018

Horizon Discovery Myeloid DNA Reference Standard

Horizon Discovery launched its Myeloid DNA Reference Standard, a large cell-line derived myeloid cancer reference standard designed to enable faster, more reliable, and more cost-effective assay validation. The Myeloid DNA Reference Standard is latest addition to the company's portfolio of more than 100 reference standards, and has been developed using Horizon's specialist gene editing technology to contain 22 mutations across 19 genes that are commonly associated with myeloid cancer. This provides genetic testing laboratories and assay developers with a tool to effectively validate and optimize myeloid genetic tests with DNA of known genotype which closely mimics the genomic DNA format and mutations present in real patient samples. The Myeloid DNA Reference Standard contains variants in more genes than most clinical material, enabling quality assurance goals to be reached faster, the firm noted.

Sep 28, 2018

Sysmex Inostics OncoBeam EGFR Kit V2

Sysmex Inostics, a subsidiary of Sysmex, has launched the OncoBeam EGFR Kit V2 for research use only in Europe and Asia. Replacing the firm's EGFR V1 kit, the V2 kit features workflow improvements, such as minimizing hands-on time and increasing efficiency. In addition, the kit covers substantially more mutations in the EGFR gene than its predecessor.

Sysmex's tool employs the firm's BEAMing technology to detect 36 cancer-relevant EGFR mutations present in ctDNA extracted from plasma, including sensitizing mutations like exon 19 deletions and L848R, as well as the T790M resistance mutation and multiple C797S variants. The assay combines emulsion-based PCR with flow cytometry to provide sensitive detection of rare mutant molecules. According to the firm, the assay requires a minimum of 2 ml of plasma to quickly deliver a comprehensive view of EGFR mutation status across all tumor cells. 

Sep 24, 2018

Roche FoundationOne Liquid

Roche has globally launched Foundation Medicine's FoundationOne Liquid, a liquid biopsy test that can identify 70 of the most commonly mutated genes in solid tumors, as well as microsatellite instability. The test complements FoundationOne CDx, the company's tissue-based genomic profiling test, and is different from FoundationAct, the firm's first liquid biopsy assay, which analyzed 62 genes and did not report MSI.

Sep 24, 2018

Mawi DNA Technologies iSWAB Cell Stabilization Line

Mawi DNA Technologies has launched the iSWAB-Cells platform. The system is designed to collect and stabilize intact cells for up to four weeks at room temperature, allowing researchers to perform multiple omics analyses from a single sample. The family of products includes the iSWAB noninvasive buccal cell collection system as well as a separate stabilization buffer for cells within different biological matrices.

Sep 21, 2018

Paragon Genomics ParagonDesigner

Paragon Genomics has launched ParagonDesigner, a web-based tool that enables rapid design of CleanPlex Custom NGS Panels. The online portal features a streamlined, user-friendly interface that simplifies the assay design process, allowing researchers to build customized next-generation sequencing assays for their specific needs. The custom panels are powered by Paragon's CleanPlex technology, an ultra-high multiplexed PCR-based target enrichment chemistry that makes it possible to include a large number of genomic targets in a single assay. 
 
With ParagonDesigner, users define the content of their custom NGS assays by submitting their targets online. ParagonDesigner features a database of more than 1,300 pre-designed, clinically-relevant human genes, allowing CleanPlex Custom NGS Panels to be instantly assembled for most applications. The design tool also issues a report on the estimated panel size and design coverage for review prior to submission. Custom NGS panels are delivered in two to four weeks, the company said.
Sep 20, 2018

Precipio EGFR Liquid Biopsy Kit

Precipio has launched a new liquid biopsy ICEme kit, which uses the company's ICE-COLD PCR technology to enrich and detect cancer mutations in EGFR exons 18, 19, 20, and 21. The kit uses either qPCR or Sanger platforms with sensitivity down to 0.1 percent allele frequency. The new product complements Precipio's previously-launched TKI-resistance detection kit, which includes assays for EGFR exon 20 T790M and C797S resistance mutations.

Sep 19, 2018

Genomenon Mastermind Genomic Search Engine

The latest release of Genomenon's Mastermind Genomic Search Engine indexes approximately 500,000 new genomic variants from supplemental data found in scientific publications. Most precision medicine tools have not been able to provide insight into supplemental data without manual curation due to the lack of a common file format, the company noted. Supplemental data is often published as an Excel, PDF, .csv, Word, text, or image file. Genomenon said that it overcame this challenge by engineering its indexing pipeline to ingest these different file formats and applying its proprietary Genomic Language Processing technology to index the content for easy retrieval by researchers. 

Sep 19, 2018

Circulogene BRCA1/2 Testing

Circulogene has included somatic BRCA1 and BRCA2 blood testing to its testing menu. The addition of somatic BRCA1/2 testing allows the company to perform paired somatic and germline testing, the Birmingham, Alabama-based molecular diagnostics firm said. The paired testing is a single blood-tube test that can detect acquired mutations and inherited variants in patients with advanced breast, ovarian, and other cancers.

Sep 18, 2018

Roche Navify Clinical Trial Match, Navify Publication Search

Roche has launched two Navify clinical decision support apps, Navify Clinical Trial Match and Navify Publication Search, to help oncologists access clinical trial information and publications. Both are available on the Navify Tumor Board platform.

The Navify Clinical Trial Match app identifies clinical trial options from 11 international registries, based on patient-specific attributes such as age, sex, biomarkers, and various tumor attributes. The registries include ClinicalTrials.gov, the German Clinical Trials Registry, and the European Clinical Trials Registry. The Navify Publication Search app mines several publication sources, including PubMed, the American Society of Clinical Oncology, and the American Association of Central Cancer Registries, for relevant literature. The content of both apps is provided by MolecularMatch, a clinical informatics company.

Roche said it plans to add more apps, including from partners and third parties, in the future.

Sep 18, 2018

Amsbio Circulating Tumor DNA Reference Standards

Amsbio has launched a new range of circulating tumor DNA reference standards: a set of highly characterized, quantitative multiplex quality controls to support the development of new assays. The standards are engineered to mimic the fragmentation profile of nucleosomal ctDNA (aproximately 166 bp) observed in real patient samples across a range of allele frequencies. Pre-validated by digital PCR, the kits include cancer-associated mutations in EGFR, PIK3CA, NRAS and KRAS, and are available as purified DNA or in a synthetica plasma.

Sep 13, 2018

Viracor Eurofins CMV Resistance:Letermovir

Viracor Eurofins has launched CMV Resistance:Letermovir, a cytomegalovirus gene sequencing assay for the detection of resistance to Prevymis (letermovir), an antiviral for use in adult hematopoietic stem cell transplant patients. The assay is available as a standalone test or as a complete panel with the other CMV drugs as CMV Resistance: Letermovir, Ganciclovir, Foscarnet, Cidofovir. Viracor Eurofins said that resistance to Prevymis has not been detected in treatment-naive patients, but noted that clinical trials have shown that resistance can develop in the UL56 gene after exposure for some HSCT patients. 

Pages

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.